Navigation Links
Sanofi Withdraws Anti-obesity Drug in US

French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.

A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States.

"Sanofi-Aventis will work towards submitting the rimonabant file to the FDA at a future date," the company said, adding that it will "undertake the necessary discussions with the FDA to determine the required modifications to its file."

The FDA's expert panel concluded that suicidal thoughts appeared to be a side-effect of taking Acomplia, which has been authorised in the European Union.

The FDA was expected to heed the opinion of the panel of experts and block the sale of the drug.

Sanofi had previously forecast annual sales of 3.0 billion euros (4.0 billion dollars) for the drug.

In a separate development, European regulators said they were reviewing data on the psychiatric effects of Acomplia.

The European Medicines Agency (EMEA) said it expected to announce its conclusions at the end of a July 16-19 meeting.

The agency "is currently reviewing the available data on psychiatric events (in particular suicidal ideation and depression-related events)," it said.

Acomplia has been authorised in 37 countries and is currently sold in 18.


'"/>




Page: 1

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Diabetes II May Be Controlled By Sanofis New Obesity Pill
4. Sanofi-Aventis Allows Thais To Make Plavix
5. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
6. Hospital Withdraws McDonalds Reward Scheme
7. Beef Firm in US Withdraws Its Products from Markets After E. Coli Outbreak.
8. Anti-obesity drugs for FDA approval
9. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
10. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Ann Arbor, MI (PRWEB) , ... December 07, ... ... offering insurance and financial consultation services from offices located in South Lyon, Dewitt, ... drive to benefit a basketball coach who needs treatment for a brain tumor. ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from ... securement tape is painful for her. "This is why the co-inventor and I have ... said. , They then created a prototype of the patent-pending AV-AIR, a device that ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals ... study was published in the prestigious Journal of Veterinary Science & Medical Diagnosis. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. ... season by donating a portion of proceeds to two local organizations: North Chicago Animal ... Control & Friends is a team of authorized and trained volunteers who support ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From ... Folio: Marketing Awards competition. Live From won in the Use of Social Media ... ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  The Corporate ... healthcare manager to call them anytime at 866-714-6466 if ... managers to sell more drugs. Aside from the innocent ... taxpayers as well, because often-times these practices target Medicare recipients ... http://photos.prnewswire.com/prnh/20161206/446240 ...
(Date:12/7/2016)... READING, Mass. , Dec. 7, 2016 /PRNewswire/ ... and Trace Network for connecting the Life Sciences ... the global marketplace, today announced that Tjoapack has ... European pharmaceutical manufacturing customers comply with the rapidly ... Chain Security Act (DSCSA) in 2017 and the ...
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
Breaking Medicine Technology: